Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.

ABSTRACT:

Introduction

The prognosis of patients with refractory or relapsed AML (R/R-AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes.

Patients and methods

Our retrospective, single-center study of 53 R/R-AML patients with a median follow-up time of 11.0 months compared standard salvage chemotherapy (FLAG-Ida or HAM in n = 35 patients) with a combination of venetoclax (VEN) and FLAG-Ida (FLAVIDA in n = 18 patients) concerning safety and efficacy.

Results

Regarding the primary endpoints, there was a statistically significant increased event free survival (EFS) in the FLAVIDA group compared to patients with standard chemotherapy base

SUBMITTER: Wille K 

PROVIDER: S-EPMC11613577 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature